The Chief Executive Officer of the Drug Regulatory Authority of Pakistan (DRAP) met with the Chairman of the Egyptian Drug Authority (EDA) to strengthen bilateral regulatory cooperation. The discussion covered enhanced coordination, regulatory reliance, joint initiatives, and capacity‑building programs, and included praise from DRAP for EDA’s recent WHO Global Benchmarking Tool Level 3 recognition for medicines and vaccines.
During the meeting both agencies explored ways to improve mutual coordination and streamline regulatory processes. Topics included mechanisms for regulatory reliance—whereby authorities can draw on each other’s assessments to reduce duplication—and the development of joint regulatory initiatives to accelerate access to safe and effective products.
Capacity building was a central theme, with the two sides emphasizing programs designed to build resilient, efficient regulatory systems. Planned activities aim to share technical expertise, improve regulatory workflows and strengthen institutional capabilities to better protect public health.
Dr. Obaidullah, CEO of DRAP, commended the EDA on achieving WHO GBT Level 3 maturity for medicines and vaccines, a recognition that signals a high level of regulatory performance and sets a noteworthy benchmark in the Eastern Mediterranean region.
The meeting reinforces DRAP’s commitment to international collaboration and regulatory excellence and signals an intent by both authorities to pursue closer cooperation and practical steps that will help ensure timely access to quality therapeutic goods for populations in Pakistan, Egypt and the wider region.
